-
Mashup Score: 14FDA Approves Amivantamab with Chemo for First-Line NSCLC with EGFR Exon 20 Insertion Mutations [EXCLUSIVE VIDEO] - 2 month(s) ago
FDA grants approval for amivantamab-vmjw in lung cancer treatment. Find out how this therapy is changing the landscape of NSCLC treatment.
Source: oncologytube.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6
/PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from the Phase 3 PAPILLON study evaluating…
Source: www.prnewswire.comCategories: Hem/Oncs, Latest HeadlinesTweet-
🔥🚨@OncoAlert Hot off the press. Press release by @JanssenUS Phase 3 #PAPILLON study, of #Amivantamab-vmjw in combination with chemo vs chemo in pts with advanced non-small cell #LungCancer with #EGFR #Exon20 mutations, met primary endpoint ⬆️ #PFS. 👇🏼 https://t.co/U28oQm0pVZ https://t.co/4qgx8pJhVP
-
-
Mashup Score: 0
During a Targeted Oncology™ Case-Based Roundtable™ event, Joshua K. Sabari, MD, discussed research supporting the use of amivantamab for patients with non–small cell lung cancer and an EGFR exon 20 insertion, including data comparing with real-world cohorts of similar patients treated with other agents.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Joshua K. Sabari, MD, discussed #amivantamab for patients with #NSCLC and an EGFR exon 20 insertion. #lcsm | @Perlmutter_CC @JSabari https://t.co/vEerD6iLrq
-
-
Mashup Score: 0Amivantamab Shows Long-term Efficacy/Safety in Post-Platinum EGFR Exon 20 Insertion+ NSCLC - 1 year(s) ago
Amivantamab treatment continued to show tolerability and efficacy in patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations whose disease progressed on platinum-based chemotherapy.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Amivantamab treatment continued to show tolerability and efficacy in patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations whose disease progressed on platinum-based chemotherapy. #NSCLC https://t.co/7KK19PotSj
-
-
Mashup Score: 0European Lung Cancer Congress | OncologyPRO - 1 year(s) ago
OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts,
Source: oncologypro.esmo.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
🚨🔥3/3 Long-term analysis of #Amivantamab in #patients with #EGFR Exon 20 insertion mutated #NSCLC. Link to #ELCC23 abstract: 👉 https://t.co/AF68zt7TSJ Link to @ASCOPost article: 👉 https://t.co/iWMfhisFmP @EGFRResisters @Exon20Group #LungCancer #KnowledgeConquersCancer
-
-
Mashup Score: 0
Amivantamab-vmjw conferred long-term clinical response in patients with advanced non-small cell lung cancer and EGFR exon 20 insertion mutations, according to data from the agent’s manufacturer. Researchers observed the benefit with amivantamab-vmjw (Rybrevant, Janssen), an EGFR and MET bispecific antibody, specifically among patients whose disease had progressed on previous platinum-based
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Amivantamab-vmjw shows durable activity in subgroup of patients with advanced NSCLC. https://t.co/RhzboNxgds @JanssenUS #lazertinib #amivantamab #nonSmallCellLungCancer #LungCancer #HemOnc #OncAlert #MedEd
-
-
Mashup Score: 2Durable efficacy of amivantamab in mutated NSCLC - 1 year(s) ago
Updated results from the CHRYSALIS trial in pretreated NSCLC with EGFR Exon 20 insertion mutations
Source: Daily ReporterCategories: Hem/Oncs, Latest HeadlinesTweet-
#ELCC23, IMO *THE slide* of the 1st day by @Piuchagarrido #LCSM Long-term analysis of #Amivantamab in pts with EGFR Ex20ins, confirming that 13% of pts remained on treatment for a median duration of 2.6 years ◾️mPFS: 6.9 months (95% CI, 5.6–8.8) ◾️mOS: https://t.co/tMZRJlSYmh… https://t.co/IsUvFsJX7x https://t.co/XozYMjPiUQ
-
-
Mashup Score: 1
Erminia Massarelli, MD, PhD, MS, discusses the efficacy outcomes of the CHRYSALIS trial of amivantamab in patients with non–small cell lung cancer and an EGFR exon 20 insertion.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Erminia Massarelli, MD, PhD, MS, discusses the efficacy outcomes of the CHRYSALIS trial of #amivantamab in patients with non–small cell lung cancer and an EGFR exon 20 insertion. #NSCLC #lcsm | @cityofhope https://t.co/TPC9qBHlHo
-
-
Mashup Score: 0Lung Cancer Archives | VJOncology - 2 year(s) ago
Welcome to the Lung Channel. Explore the latest updates in lung cancer, including expert interviews from major international congresses and news by subtype.
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
We had a great catch up with Professor Byoung Chul Cho at #WCLC22 to discuss #amivantamab and #lazertinib in treatment-naive #EGFR-mutant #NSCLC and more For our latest news in #lungcancer, see our @VJOncology Lung Cancer Channel 👉https://t.co/lJa7bThu5c👈 #lcsm #sclc https://t.co/tj0M2RxPmM
-
-
Mashup Score: 1
CHRYSALIS-2 findings presented at ESMO Annual Congress 2021 suggest that RYBREVANT® and lazertinib combination has encouraging anti-tumor activity in this population that has exhausted standard-of-care treatments
Source: Content Lab U.S.Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ESMO21 new data on amivantamab in combination with lazertinib shows early activity in patients with non-small-cell lung cancer whose disease has progressed after both osimertinib and platinum-based chemotherapy >>> https://t.co/VwqxqD33dp #Amivantamab #Lazertinib #NSCLC #LCSM
-
FDA Approves Amivantamab with Chemo for First-Line NSCLC with EGFR Exon 20 Insertion Mutations [EXCLUSIVE VIDEO] https://t.co/cP01LYtN8F @nicogirardcurie @institute_curie @FDAOncology #Amivantamab https://t.co/9F4ug8ASpo